ESLA Q1 2023 Earnings — Estrella Immunopharma, Inc. Revenue & Financial Results | Market Cap Arena

ESLAEstrella Immunopharma, Inc.

$53M

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$149,650

Net Income

-$63,325

EPS (Diluted)

$-0.03

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$275,718

Free Cash Flow

-$275,718

Stock-Based Comp.

$102,399

Balance Sheet

Total Assets

$10M

Total Liabilities

$3M

Stockholders' Equity

$7M

Cash & Equivalents

$29,390

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$149,650	-$168,292	+11.1%
Net Income	-$63,325	-$168,292	+62.4%